|Last Price$108.04||Day Change (%)0.64%|
|Open Price$107.89||Day Change ($)0.69|
|Day Range107.72–108.33||52-Week Range85.50–108.33|
As of Fri 09/19/2014 12:28 PM EST | USD
Johnson & Johnson Responds to Ebola Crisis With Commitment to Accelerate Vaccine Program in Collaboration With the US National Institutes of Health (NIH) and Provide Humanitarian Relief Aid
Johnson & Johnson to Participate in 2014 Morgan Stanley Health Care Conference
We Are Mesh Survivors Applauds Verdict against Johnson and Johnson on Pelvic Mesh: Jury Delivers $3.27 Million Verdict for Plaintiff Jo Huskey in Johnson & Johnson Federal Trial on Pelvic Mesh Devices in West Virginia
Top managers continue to focus on higher-quality dividend-paying stocks in a fully valued market.
There can be good reasons to own dividend-focused ETFs, but investors looking for pure income may be better off in individual stocks, says Morningstar's Josh Peters.
Our model portfolio continues to outpace the market.
Unexpectedly robust sales of hepatitis C drug Olysio helped lift the drug giant’s pharma segment, while medical devices struggled, says Morningstar’s Damien Conover.
Research and Markets: Global Infectious Disease Treatment Market 2014-2018: Key Vendors Are F. Hoffmann-La Roche, Gilead Sciences, GSK, J & J Merck & Pfizer
Research and Markets: Global Moderate Psoriasis Therapeutics Pipeline Report 2014 - 17 Companies & 23 Drug Profiles
A group of top managers continue to keep looking for good investment opportunities, while taking full advantage of a rising (and potentially overvalued) market to book some gains.